Dual Kinase Therapy Slows BRAF Mutated Metastatic Melanoma

VIENNA (IMNG) – Combination therapy with a BRAF inhibitor and a MEK inhibitor extended progression-free survival by more than 3 months in patients with BRAF V600 mutated metastatic melanoma, early clinical findings suggest.”This is the first kinase-kinase combination to show enhanced antitumor activity over the single agent,” and the first to show that specific oncogenic toxicities may be reduced with combination therapy, said Dr. Georgina Long of the Melanoma Institute Australia in Sydney.In a phase… Read More